ArrowArtboardCreated with Sketch.Title ChevronTitle ChevronIcon FacebookIcon LinkedinIcon Mail ContactPath LayerIcon MailPositive ArrowIcon PrintIcon Twitter

Daiwa unit launches $135m fund to support drug discovery

DCI Partners targets Japan and Taiwan biotech startups developing COVID remedies

Investors in DCI Partners's drug discovery fund include government entities in Japan and Taiwan. (Photo courtesy of the company)

TOKYO -- DCI Partners, a venture capital fund manager of Daiwa Securities Group, has launched a 14 billion yen ($135 million) investment fund focused on drug discovery projects.

The fund is one of the largest of its type in Japan, created to pool money from government-affiliated entities in Japan and Taiwan, among others, for investment into startups in Japan and Taiwan. It aims to fund efforts to develop new technologies for producing coronavirus drugs and for genome editing.

Sponsored Content

About Sponsored Content This content was commissioned by Nikkei's Global Business Bureau.

Discover the all new Nikkei Asia app

  • Take your reading anywhere with offline reading functions
  • Never miss a story with breaking news alerts
  • Customize your reading experience

Nikkei Asian Review, now known as Nikkei Asia, will be the voice of the Asian Century.

Celebrate our next chapter
Free access for everyone - Sep. 30

Find out more